Bispecific Therapies in Relapsed/Refractory Multiple Myeloma

January 23, 2025

Opinion

Video

Panelists discuss how bispecific antibodies targeting B-cell maturation agent, GPRC5D, and FcRH5 are transforming relapsed/refractory multiple myeloma treatment (R/R MM) with promising efficacy, manageable safety profiles, and convenient off-the-shelf administration.

EP: 1.Brief Overview of Therapeutic Landscape for R/R MM

EP: 2.Comparative Outcomes: Talquetamab vs Physician's Choice in R/R Multiple Myeloma

EP: 3.MajesTEC-1: Identifying the Optimal Patient Population for Teclistamab

EP: 4.Elranatamab Dosing Strategies: Implications for Community Practice

EP: 5.Navigating Post–CAR T Progression: Therapy Selection and Targeting

Now Viewing

EP: 6.Bispecific Therapies in Relapsed/Refractory Multiple Myeloma

EP: 7.ASH Top Takeaways of Bispecific Antibodies in R/R Multiple Myeloma

Video content above is prompted by the following:

What are some data updates at ASH 2024 that you are excited about?
Before we close, I would like each of you to share some key takeaways and clinical pearls on the treatment of patients with R/R MM in the era of bispecifics for your community colleagues.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!